178445-89-1

Usage

Uses

Used in Medicinal Chemistry:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a chiral molecule for its potential application in the development of new drugs. (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol's unique structure may allow it to interact with biological targets in novel ways, leading to the discovery of new therapeutic agents.
Used in Material Science:
In the field of material science, (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a building block for the synthesis of new materials with specific properties. Its chiral nature and complex structure may contribute to the creation of materials with unique optical, electronic, or mechanical characteristics.
Used in Organic Synthesis:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as an intermediate in organic synthesis for the production of other complex molecules. Its chiral center and diverse functional groups make it a valuable starting material for the synthesis of various organic compounds with potential applications in different industries.
Used in Pharmaceutical Industry:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a key component in the development of new pharmaceuticals. Its unique structure may offer novel mechanisms of action or improved pharmacokinetic properties, leading to more effective treatments for various diseases.
Used in Chemical Research:
In the field of chemical research, (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a model compound for studying the effects of chirality on molecular interactions and reactivity. This research may provide valuable insights into the design of new chiral molecules with specific properties and applications.

Upstream product

• 178445-86-8 2[[3-(3,4-dimethyoxyphenyl)-1-oxopropyl]phenoxy]acetic acid 1,1-dimethylester 
• 178445-83-5 3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)-1-propanone 
• 178445-80-2 (E)-1-(3,4-dimethoxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one 
• 121-71-1 3-Hydroxyacetophenone 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 215168-57-3 3,4-dimethoxy-3’-hydroxychalcone 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 111-42-2 2,2'-iminobis[ethanol] 

Downstream Products

• 195202-03-0 (S)-((R)-1-(3-(2-tert-butoxy-2-oxoethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propyl) piperidine-2-carboxylate 

Relevant academic research and scientific papers

RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have grea

NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides neuroprotective compounds along with their use in treating disease such as Parkinson's disease (PD). The compounds can be used as inhibitors for Parthanatos Associated AIF (apoptosis-inducing factor) Nuclease (PAAN), also known as macrophage migration inhibitor factor (MIF).

Design and Combinatorial Development of Shield-1 Peptide Mimetics Binding to Destabilized FKBP12

On the basis of computational design, a focused one-bead one-compound library has been prepared on microparticle-encoded PEGA1900 beads consisting of small tripeptides with a triazole-capped N-terminal. The library was screened towards a double

Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35

FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.

MULTIMERIC PIPERIDINE DERIVATIVES

The technology relates in part to compounds that bind to multimeric ligand binding regions, referred to herein as "multimeric compounds." In certain examples, the multimeric compounds provided herein bind to and multimerize polypeptides that bind to rimiducid, such as for example, chimeric polypeptides that comprise FKBP12 polypeptide variant regions. Multimeric compounds provided include those having a structure of Formula I. Where A, Z, Y, Z' and A' moieties are described herein.

Synthetic process of homodimer of FKBP ligand

The invention discloses a synthesis process of homodimer of FKBP ligand and belongs to an improved synthesis process of AP1903, wherein the homodimer of FKBP ligand refers to AP1903. According to theoptimized route of the synthesis process chooses, (S)-piperidine-2-methyl formate is connected to the compound Cpd9' as selected, an acid Cpd6' obtained after ester hydrolysis is easier to be purified by post-treatment purification, and precipitation or extraction treatment can be chosen by the post-treatment purification. Although the total reaction steps of the synthetic route in the prior literature are the same as the optimized route of the invention, the synthetic route in the prior literature belongs to the vertical route, and the post-treatment of the fifth, sixth and eighth steps requires column chromatography, thereby leading to a higher research and development cost. The optimized AP1903 synthetic route belongs to the parallel route, and the post-treatment is simpler and more advantageous for separation and purification, so that the cost of research and development is relatively low and the economic benefit is obviously superior to that of the synthetic route in the prior art.

A bioorthogonal small-molecule-switch system for controlling protein function in live cells

Chemically induced dimerization (CID) has proven to be a powerful tool for modulating protein interactions. However, the traditional dimerizer rapamycin has limitations in certain in vivo applications because of its slow reversibility and its affinity for

PIPECOLATE-DIKETOAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to compounds having a pipecolate diketoamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pipecolate diketoamide compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Pipecolate-diketoamides for treatment of psychiatric disorders

The present invention relates to compounds having a pipecolate diketoamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable

Pipecolate-sulfonamides for treatment of psychiatric disorders

The present invention relates to compounds having a pipecolate sulfonamide scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable